Therapeutics Company Eligible For Up to $330 Million on Successful Achievement of Prespecified Regulatory

Collaborations between companies are pivotal in driving scientific advancements and addressing unmet medical needs. A recent development in this field is the collaboration between Addex Therapeutics and Indivior PLC, focusing on the selection of clinical candidates from their gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) research. This partnership is noteworthy not only for its scientific implications but also for its potential impact on treating substance use disorders and chronic cough. $Addex Therapeutics (ADXN.US)$